Sixfold Bioscience: A Cure to Cancer?

[Nicolas Chea]

Sixfold Bioscience

A Cure to Cancer? Revolutionizing RNA Medicine through Nanotechnology

The latest
May 7, 2025

Discover how Sixfold Bioscience, founded by George Foot and Anna Perdrix Rosell, is transforming RNA medicine with their innovative nanotechnology approach. Learn how their groundbreaking platform, Mergo®, leverages natural RNA delivery mechanisms to target specific cells, solving one of the biggest challenges in biopharma. Explore the benefits of Sixfold’s technology, including precise RNA delivery, accelerated therapeutic development, and potential applications across diverse medical fields.

In addition to their £3.1m in grants, Sixfold also raised £7.8m in just a single round of equity funding (Beauhurst, 2025). 

Next-Gen RNA Delivery:
Sixfold Bioscience uses nanotechnology to develop treatments that precisely target cancerous cells. Their breakthrough technology, Mergo®, utilizes AI-driven RNA tags to deliver therapeutic RNAs to exact cell types, redefining how RNA medicines are administered.

Mergo® - The RNA Tagging Platform:
Mergo® represents a radical departure from conventional RNA delivery methods. By leveraging modified RNA molecules as vectors, Mergo® can precisely deliver RNA therapeutics to targeted tissues or cell types, overcoming limitations associated with liver-centric delivery. This innovation addresses the current gap, where almost 99% of cell types are untargetable for RNA therapeutics.

Breaking Traditional Boundaries:
Unlike traditional methods like lipid nanoparticles (LNPs) or ligands (e.g., GalNAc), Mergo® harnesses the natural mechanisms of RNA transport. Inspired by non-coding RNAs, which naturally migrate between cells, Mergo® is designed to integrate with diverse cellular shuttles, allowing targeted RNA delivery beyond the liver.

Precision and Efficiency:
Sixfold’s innovative screening platform rapidly tests multiple Mergo® variants in vivo, identifying optimal configurations for targeted delivery. This rapid iteration process reduces time and cost while enabling precise, efficient RNA transport to previously unreachable cell types.

Real-World Impact:
Sixfold’s most advanced Mergo® system has demonstrated the ability to redirect RNA molecules from the liver to the lungs with significantly lower doses and higher activity. This breakthrough paves the way for creating a complete RNA delivery map of the human body, vastly expanding the therapeutic potential of RNA-based treatments.

A Visionary Leadership Team:
Founded in 2017 by George Foot and Anna Perdrix Rosell, Sixfold Bioscience is a trailblazer in RNA delivery. Working from their London laboratories, their interdisciplinary team of chemists, biologists, and engineers continually advances the boundaries of RNA medicine.

Solving the RNA-Delivery Problem:
Traditional RNA medicines face the challenge of limited delivery to specific cells. By emulating nature’s RNA transport methods, Sixfold overcomes this barrier, providing a platform for precise and programmable delivery that aligns with the body’s own communication systems.

Unlocking the Future of RNA Medicine:
With a mission to redefine RNA therapeutics, Sixfold Bioscience is poised to catalyze the next wave of biopharma innovation. The Mergo® platform offers unprecedented control over where and how RNA molecules are delivered, marking a pivotal advance in targeted therapy.

Contact Sixfold Bioscience
Website: https://sixfold.bio
Reach out to George Foot and Anna Perdrix Rosell at https://www.linkedin.com/in/george-foot/ and https://www.linkedin.com/in/annaperdrix/ for collaboration opportunities or to learn more about their pioneering RNA delivery technology.